𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis

✍ Scribed by J. P. Devogelaer; J. P. Brown; P. Burckhardt; P. J. Meunier; S. Goemaere; K. Lippuner; J. J. Body; G. Samsioe; D. Felsenberg; T. Fashola; L. Sanna; C. E. Ortmann; U. Trechsel; J. Krasnow; E. F. Eriksen; P. Garnero


Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
170 KB
Volume
18
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Bone material properties in actively bon
✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci